Archive for January, 2013

A Spitzoid lesion

Great to get comments on this case

regards

Ian

A Spitzoid lesion

4 Comments

Skin cancer phone apps aren’t very accurate: study

Carrying on with regard to previous discussions about Apps, this has come out this month. I can email the article which is free online to anyone (http://archderm.jamanetwork.com/article.aspx?articleid=1557488#qundefined)

regards

Ian

 

Skin cancer phone apps aren’t very accurate: study

(Reuters Health) – Smartphone applications that use algorithms to analyze skin lesions may not be very good at determining which ones are cancerous, a new study suggests.

The apps are marketed as educational only and so aren’t covered as medical devices under the Food and Drug Administration’s regulations.

But that may not stop some people from relying on the inexpensive toolsinstead of going to see a dermatologist, researchers said – which could mean slower diagnosis of potentially dangerous lesions.

“There’s no substitute, at this point, for a complete skin exam performed by an expert dermatologist for picking up melanoma as well as other skin cancers,” said Dr. Karen Edison, a dermatologist from University of Missouri in Columbia who wasn’t involved in the new study.

“Just sending a picture to someone you don’t know anywhere in the world can be reassuring if it’s very clear that (the lesion) is benign, so that’s a good thing,” she told Reuters Health, “but it’s kind of fraught with other issues that we haven’t grappled with adequately, I don’t think.”

For example, even if an app makes a correct diagnosis of melanoma, that doesn’t necessarily help if the patient doesn’t know where to get a biopsy or doesn’t have insurance to pay for it, Edison said. “We’re all for technology, but we need to keep it in perspective, and make it a tool.”

For the new study, researchers used photos of 188 pre-diagnosed lesions – 60 melanomas and 128 benign lesions – to check the accuracy of four Smartphone apps made to look for melanoma in previously-taken images.

Three of those apps, which cost under $5 to own, use algorithms to determine whether a lesion is likely to be cancerous or not. The fourth sends images to a certified dermatologist for evaluation, at a price of $5 per lesion.

Of the three algorithm-based apps, the most accurate still missed 18 of the 60 melanomas, mistakenly classifying them as lower-risk, Dr. Laura Ferris from the University of Pittsburgh Medical Center in Pennsylvania and her colleagues reported Wednesday in JAMA Dermatology.

App users “need to know that that’s a pretty big risk to take,” Ferris said.

“If you delay removal or evaluation for your melanoma, it gets deeper, and the chance of it spreading and getting deadly really increases with time,” she told Reuters Health.

The dermatologist consultation app did better than the others, misdiagnosing just one out of 53 evaluable images of cancerous lesions.

All but one of the apps classified more than half of the benign, non-cancerous lesions as problematic.

The researchers said they chose not to release the commercial names of the apps evaluated because their purpose was to determine the accuracy of this type of tool, in general.

The website of a similar company that markets an app for skin lesion analysis using real-time photos, SkinVision, cautions customers to, “Never disregard professional medical advice, or delay in seeking it, because of something you have read on SkinVision. Do not rely on information from SkinVision instead of seeking professional medical advice.”

Likewise, the website for the Mole Detective app says, “Always defer to a medical professional if you feel that a mole looks suspicious. Mole Detective’s intent is not to diagnosis but to help you better track the symptoms of melanoma at home.”

Ferris said there are certain dermatology apps that can help patients.

“There are apps that will do things like teach you about melanomas,” she said. “There are ones that will remind you to do your own skin check – that’s great.”

Both researchers said teledermatology – giving people who live in rural areas, for example, the chance to consult with a dermatologist through photos or video – can be useful. Edison, for example, once used it to diagnose a farmer living hours away with melanoma during harvest season.

But they agreed that for now – and probably for the foreseeable future – machines and apps can’t beat in-person exams when it comes to checking for skin cancer.

2 Comments

Pain and skin cancer

I discussed this with a few people last year and came across this article during the holidays.  I do not believe their pain figures for BCC and SCC as they seem far too high. It’s probably because it is a hospital setting and they see more advanced cases.

Regards

Ian

 

Pain and Skin Cancer

Pain is a significant predictor of squamous cell carcinoma compared to basal cell carcinoma, according to results of a recent study.

Investigators with Wake Forest University Baptist Medical Center conducted an institutional review board-approved study, analyzing data on 576 nonmelanoma skin cancers (NMSC) from 478 patients with a mean age of 68.8, . Of those patients, 353 had basal cell carcinoma (BCC) and 223 had squamous cell carcinoma (SCC). The patients used a visual analogue scale to rate the pain and itch they experienced.

For both types of NMSC, itch was the most reported symptom, at 43.5% in SCC and 33.4 % in BCC. The pain prevalence was 39.8 % for patients with SCC, compared to 17.7 % of patients with BCC.

With each one-point increment in visual analogue scale for pain, the odds of having SCC rather than BCC increased by 30 %, according to the study. There was nearly a fourfold increase in the likelihood of a patient having SCC versus BCC when the score for pain was greater than two (odds ratio=3.94; 95 % confidence interval, 2.49-6.23).

“With an increasingly aging population, patients often present with numerous BCCs and SCCs, and it is often difficult for the clinician to prioritize lesion biopsy and removal,” the study authors wrote. “Thus, there is a need for better clinical tools to aid the physician in selecting lesions most likely to be SCCs.”

The study was published in the December issue of JAMA Dermatology, formerly Archives of Dermatology.

 

7 Comments